Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Aricept ODT, Aricept
Synonyms :
Class :
Acetylcholinesterase Inhibitors
Brand Name :
Aricept ODT, Aricept
Synonyms :
Class :
Acetylcholinesterase Inhibitors
Dosage Forms & Strengths
Tablet
5mg
10mg
23mg
Tablet-oral disintegrating
5mg
10mg
Mild/moderate: 5 mg orally daily, may increase up to10 mg after 4-6 weeks Moderate/severe: 5 mg/day orally, increase up to 10 mg/day after 4-6 weeks; and after 3 months increase up to 23 mg/day Administration Take at bedtime and dissolve the drug under the tongue and follow with water
Dose Adjustments
Dose Modification Renal Impairment: Not Available Hepatic Impairment: Not Available
Safety and efficacy not established
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
may increase the bradycardic effect of bradycardia-causing agents
may have an increased constipating effect when combined with clozapine
may have an increased anticholinergic effect when combined with glycopyrrolate
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
zolpidem: they may decrease the therapeutic effect of anticholinesterases
ceritinib: they may increase the bradycardic effect of Bradycardia-Causing Agents
clozapine: they may increase the bradycardic effect of Bradycardia-Causing Agents
fingolimod: they may increase the bradycardic effect of Bradycardia-Causing Agents
secretin: they may increase the bradycardic effect of Bradycardia-Causing Agents
sincalide: they may increase the bradycardic effect of Bradycardia-Causing Agents
aclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
cimetropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
glycopyrrolate: they may increase the bradycardic effect of Bradycardia-Causing Agents
ipratropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
levosulpiride: they may increase the bradycardic effect of Bradycardia-Causing Agents
atropine: they may increase the bradycardic effect of Bradycardia-Causing Agents
oxatomide: they may increase the bradycardic effect of Bradycardia-Causing Agents
potassium chloride: they may increase the bradycardic effect of Bradycardia-Causing Agents
revefenacin: they may increase the bradycardic effect of Bradycardia-Causing Agents
tiotropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
umeclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
siponimod: they may increase the bradycardic effect of Bradycardia-Causing Agents
deferiprone: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
dexamethasone: it may increase the bradycardic effect of Bradycardia-Causing Agents
azelastine: it may increase the bradycardic effect of Bradycardia-Causing Agents
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
It may enhance QTc interval when combined with lithium
it may enhance the qtc interval when combined with lofexidine
bradycardia causing agents increase the arrhythmia-causing effect of fexinidazole
may increase the bradycardia effect
may decrease the therapeutic effects
may have an increased anticholinergic effect when combined with cimetropium
may have an increased constipating effect when combined with eluxadoline
may have an increased anticholinergic effect when combined with anticholinergic agents
may increase the anticholinergic effect of Anticholinergic Agents
anticholinergic agents increase the ulcer-producing effect of potassium citrate
may increase the anticholinergic effect of each other when combined
may have an increased anticholinergic effect when combined with anticholinergic agents
levosalbutamol: they may decrease the therapeutic effect of anticholinesterases
oxatomide: they may increase the anticholinesterase effect of anticholinesterases
bradycardia-causing agents enhance arrhythmogenic effect of fexinidazole
may enhance the rate of excretion resulting in the lower serum level
may enhance the rate of excretion resulting in the lower serum level
may enhance the rate of excretion resulting in the lower serum level
may enhance the rate of excretion resulting in the lower serum level
may enhance the rate of excretion resulting in the lower serum level
it may reduce the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of anticholinergic agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
It may increase the neurotoxic effect of Antipsychotic Agents
it may increase the bradycardic effect of Beta-Blockers
it may increase the bradycardic effect of Beta-Blockers
it may increase the bradycardic effect of Beta-Blockers
it may increase the bradycardic effect on other Bradycardia-Causing Agents
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Acetylcholinesterase Inhibitors
it may enhance the risk of adverse effects of Acetylcholinesterase Inhibitors
it may enhance the risk of adverse effects of Acetylcholinesterase Inhibitors
it may enhance the risk of adverse effects of Acetylcholinesterase Inhibitors
it may enhance the risk of adverse effects of Acetylcholinesterase Inhibitors
it may reduce the neuromuscular blocking effect of Neuromuscular Blocking Agents
it may reduce the neuromuscular blocking effect of Neuromuscular Blocking Agents
it may reduce the neuromuscular blocking effect of Neuromuscular Blocking Agents
it may reduce the neuromuscular blocking effect of Neuromuscular Blocking Agents
it may reduce the neuromuscular blocking effect of Neuromuscular Blocking Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
corticosteroids may enhance the adverse/toxic effect of acetylcholinesterase Inhibitors
corticosteroids may enhance the adverse/toxic effect of acetylcholinesterase Inhibitors
corticosteroids may enhance the adverse/toxic effect of acetylcholinesterase Inhibitors
corticosteroids may enhance the adverse/toxic effect of acetylcholinesterase Inhibitors
corticosteroids may enhance the adverse/toxic effect of acetylcholinesterase Inhibitors
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may reduce the effect of neuromuscular-blocking agents
may reduce the effect of neuromuscular-blocking agents
may reduce the effect of neuromuscular-blocking agents
may reduce the effect of neuromuscular-blocking agents
may reduce the effect of neuromuscular-blocking agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may decrease the neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may decrease the neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may decrease the neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may decrease the neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may decrease the neuromuscular-blocking effect when combined with neuromuscular-blocking agents
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
reduce the therapeutic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
spironolactone and hydrochlorothiazide
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
it increases the concentration of thiazide and its diuretics in the serum
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may have an increased tachycardic effect when combined with cannabinoid products
may have an increased tachycardic effect when combined with cannabinoid products
donepezil together with cisapride lead to an elevation of the QTc interval
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
Combining donepezil with pranlukast may cause a reduction in the donepezil’s metabolism
The potential for increased CNS depression risk or seriousness occurs when donepezil is used together with pinazepam
they decrease the efficacy of anticholinergic agents
they decrease the efficacy of anticholinergic agents
they decrease the efficacy of anticholinergic agents
they decrease the efficacy of anticholinergic agents
they decrease the efficacy of anticholinergic agents
When donepezil is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when donepezil is used together with fencamfamin
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
anticholinestereses: they may increase the toxic effect of mu-opioid receptor agonists
When donepezil is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When donepezil is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
It may enhance the risk of adverse effects when combined with anticholinesterases
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may decrease the neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may enhance the concentration of serum when combined with thiazide diuretics
may enhance the concentration of serum when combined with thiazide diuretics
When encainide is used together with donepezil, this leads to a reduction in the encainide’s metabolism
When donepezil is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
may have a decreased therapeutic effect when combined with anticholinergic agents
may have a decreased therapeutic effect when combined with anticholinergic agents
may have an increased tachycardic effect when combined with cannabinoid-containing products
may have an increased tachycardic effect when combined with cannabinoid-containing products
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
When acepromazine is used together with donepezil, this leads to enhanced risk or seriousness of CNS depression
may have an increased bradycardic effect when combined with beta-blockers
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
amoxicillin/omeprazole/rifabutin
may decrease the therapeutic effect when combined with gastrointestinal agents
may decrease the therapeutic effect when combined with gastrointestinal agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
When indisulam is used together with donepezil, this leads to a reduction in donepezil metabolism
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
When donepezil is used in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
May diminish the therapeutic effect of Anticholinergic Agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
hydrocodone/chlorpheniramine/pseudoephedrine
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect
may increase the immunosuppressive effect of corticosteroids
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
bradycardia-causing agents increase the efficacy of ivabradine
may increase the toxic effect
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may decrease the therapeutic effect of dipyradimole
may increase the adverse effect of corticosteroids
may increase the toxic effect of corticosteroids
may enhance the serum concentration of anticholinergic agents
may enhance the serum concentration of anticholinergic agents
may enhance the serum concentration of anticholinergic agents
may enhance the serum concentration of anticholinergic agents
may increase the bradycardic effect of beta blockers
may decrease the therapeutic effect of anticholinergic agents
acrivastine and pseudoephedrine
may decrease the therapeutic effect of anticholinergic agents
may increase the bradycardic effect of beta blockers
may increase the bradycardic effect of bradycardia-causing agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may enhance the risk of adverse effect of acetylcholinesterase inhibitors
may decrease the therapeutic effect of Anticholinergic Agents
may enhance the bradycardic effect of beta blockers
may enhance the bradycardic effect of bradycardia-causing agents
may increase the toxic effect of cholinergic agonists
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of Anticholinergic Agents
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may have an increased anticholinergic effect when combined with anticholinergic agents
may enhance the anticholinergic effect of Anticholinergic agents
may increase the anticholinergic effect of anticholinergic agents
may increase the hypotensive effect of blood pressure lowering agents
may decrease the therapeutic effect of Anti-cholinergic Agent
may increase the toxic effect of other Anticholinergic Agents
may diminish the absorption when combined with nitroglycerin
may increase the neurotoxic effect of Antipsychotic Agents
may have an increasingly adverse effect when combined with glucagon
anticholinergic agents increase the toxicity of topiramate
may decrease the therapeutic effect of Anticholinergic Agents
may increases the adverse effect of Opioid Agonists
buprenorphine,long-acting injection
may increases the adverse effect of Opioid Agonists.
acetaminophen/doxylamine/dextromethorphan
may decrease the therapeutic effect of Anticholinergic Agents
acetaminophen/doxylamine/dextromethorphan
may increase the adverse effect of other Anticholinergic Agents
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
may enhance the risk of adverse effect
May decrease the therapeutic effect when combined
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may diminish the therapeutic effect of Acetylcholinesterase Inhibitors
may increase the bradycardic effect of each other
may decrease the therapeutic effect of Anticholinergic Agents
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
midodrine: they may increase the bradycardic effect of Bradycardia-Causing Agents
ozanimod: they may increase the bradycardic effect of Bradycardia-Causing Agents
tofacitinib: they may increase the bradycardic effect of Bradycardia-Causing Agents
may decrease the therapeutic effect of Acetylcholinesterase Inhibitors
may decrease the therapeutic effect of Acetylcholinesterase Inhibitors
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
It may enhance the risk of adverse effects when combined with Androgens
It may enhance the risk of adverse effects when combined with Androgens
It may enhance the risk of adverse effects when combined with hormone antagonists
may decrease the therapeutic effect when combined with anticholinergic agents
may decrease the therapeutic effect when combined with anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increasingly adverse effect when combined with other anticholinergic agents
may have an increased tachycardic effect when combined with cannabinoid products
may have an increased tachycardic effect when combined with cannabinoid products
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may enhance the serum concentration of anticholinergic agents
may enhance the serum concentration of anticholinergic agents
may have a decreased therapeutic effect when combined with anticholinergic agents
may have a decreased therapeutic effect when combined with anticholinergic agents
may have a decreased therapeutic effect when combined with anticholinergic agents
may have a decreased therapeutic effect when combined with anticholinergic agents
may have a decreased therapeutic effect when combined with anticholinergic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
amifampridine: they may increase the bradycardic effect of Bradycardia-Causing Agents
edrophonium: they may increase the bradycardic effect of Bradycardia-Causing Agents
dipyridamole: they may increase the bradycardic effect of Bradycardia-Causing Agents
mirabegron: they may increase the bradycardic effect of Bradycardia-Causing Agents
nitroglycerin: they may increase the bradycardic effect of Bradycardia-Causing Agents
succinylcholine: they may increase the bradycardic effect of Bradycardia-Causing Agents
topiramate: they may increase the bradycardic effect of Bradycardia-Causing Agents
fluorouracil: they may increase the bradycardic effect of Bradycardia-Causing Agents
methoxsalen: they may increase the bradycardic effect of Bradycardia-Causing Agents
porfimer: they may increase the bradycardic effect of Bradycardia-Causing Agents
midodrine: they may increase the bradycardic effect of Bradycardia causing agents
amifampridine: they may increase the therapeutic effect of acetylcholine inhibitors
dipyridamole: they may increase the therapeutic effect of acetylcholine inhibitors
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
bunazosin (Not available in the United States)
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
alpha-1 blocker: they may increase the therapeutic effect of acetylcholine inhibitors
beta blockers: they may increase the therapeutic effect of acetylcholine inhibitors
succinylcholine: they may increase the therapeutic effect of acetylcholine inhibitors
tofacitinib: they may increase the therapeutic effect of acetylcholine inhibitors
may increase the efficacy of each other when combined
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may have an increasingly adverse effect when combined with acetylcholinesterase inhibitors
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
the anticholinergic effect of anticholinergic agents may be enhanced
the anticholinergic effect of chlorprothixene may be enhanced by anticholinergic agents
adverse/toxic effects of glucagon particularly gastrointestinal effects may be increased by anticholinergic agents
the rate of metabolism may be altered
When donepezil is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
ozanimod: it may enhance the bradycardic effect of Bradycardia-Causing Agents
pamidronate: it may enhance the bradycardic effect of Bradycardia-Causing Agents
valerian: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
may diminish the effects of pharmacodynamic antagonism
glycopyrrolate inhaled and formoterol
may diminish the effects through pharmacodynamic antagonism
anticholinergic agents decrease the efficacy of secretin
Adverse drug reactions:
Frequency Defined
>10%
Erythema
Papules
Headache
1-10%
Muscle spasms
Insomnia
Abdominal pain
Application site dermatitis
Constipation
Diarrhea
Application site pain
Dizziness
Abnormal dreams
Skin laceration
<1%
Edema
Post marketing Reports:
Hemolytic anemia
Heart block
QTc prolongation
Abdominal pain
Cholecystitis
Hepatitis
pancreatitis
Hyponatremia
Pregnancy warnings:
Pregnancy category: C
Breastfeeding warnings:
crosses into breast milk- Unknown
Pregnancy Categories:
Patient Information Leaflet
Generic Name: donepezil transdermal
Why do we use donepezil transdermal?
donepezil belongs to the class of Acetylcholinesterase Inhibitors, which helps to treat Alzheimer’s disease and Dementia
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
